Open access
Open access
Powered by Google Translator Translator

Pharmacology/Pharmaceutical Industry

Pfizer COVID-19 shot expanded to US children as young as 12.

12 May, 2021 | 08:53h | UTC

Pfizer COVID-19 shot expanded to US children as young as 12 – Associated Press

Counterpoint: Covid vaccines for children should not get emergency use authorization – The BMJ Opinion

Commentaries: Covid-19: FDA authorises Pfizer vaccine for children 12-15 – The BMJ AND Expert reaction to U.S. FDA authorising Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents – Science Media Centre

 

[Preprint] Meta-analysis of risk of vaccine-induced immune thrombotic thrombocytopenia following ChAdOx1-S recombinant vaccine – Overall risk is 1 in 139,000; for age 65 and over, about 1 in 1,000,000; for age under 55, between 1 in 20,000 to 60,000.

12 May, 2021 | 08:45h | UTC

Meta-Analysis of Risk of Vaccine-Induced Immune Thrombotic Thrombocytopenia Following ChAdOx1-S Recombinant Vaccine – medRxiv

 

Guideline: SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes – This guidance recommends a risk-based approach, advising against starting SGLT-2 inhibitors or GLP-1 receptor agonists in patients with three or fewer cardiovascular risk factors and without established CVD or CKD.

12 May, 2021 | 08:42h | UTC

SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline – The BMJ

Editorial: Newer drug treatments for type 2 diabetes

 

Commentary on Twitter

 

A global database of COVID-19 vaccinations

11 May, 2021 | 09:28h | UTC

A global database of COVID-19 vaccinations – Nature Human Behaviour

See website: Statistics and Research: Coronavirus (COVID-19) Vaccinations – Our World in Data

 

Commentaries on Twitter

 

Cohort study: Non-steroidal anti-inflammatory drug use is not associated with higher mortality or increased severity of COVID-19

11 May, 2021 | 09:25h | UTC

Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study – The Lancet Rheumatology

Commentaries: Largest study to date confirms non-steroidal anti-inflammatory medications do not result in worse COVID-19 outcomes – The Lancet AND Non-steroidal anti-inflammatory drug use in COVID-19 – The Lancet Rheumatology AND Ibuprofen, other NSAIDs not tied to worse COVID illness, death – CIDRAP

Related study with similar findings: Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID‐19 – Arthritis & Rheumatism

 

Commentary on Twitter

 

Analysis: Covid-19: How will a waiver on vaccine patents affect global supply?

11 May, 2021 | 09:17h | UTC

Covid-19: How will a waiver on vaccine patents affect global supply? – The BMJ

Related: In shock move, US backs waiving patents on COVID vaccines. “The development from the Biden administration draws cheers from public health researchers and ire from drugmakers.”

Related Podcast: Coronapod: Waiving vaccine patents and coronavirus genome data disputes – Nature

 

WHO lists Sinopharm COVID-19 vaccine for emergency use and issues interim recommendations.

10 May, 2021 | 01:19h | UTC

WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations – World Health Organization

Commentaries: WHO approves Sinopharm vaccine in potential boost to COVAX pipeline – Reuters AND WHO panel OKs emergency use of China’s Sinopharm vaccine – Associated Press AND WHO lists Sinopharm COVID-19 vaccine for emergency use – CIDRAP

 

Commentary on Twitter (thread – click for more)

 

Covid-19: Most people admitted to hospital after vaccination were infected before immunity could develop, research shows.

10 May, 2021 | 01:14h | UTC

Covid-19: Most people admitted to hospital after vaccination were infected before immunity could develop, research shows – The BMJ

 

Commentary on Twitter

 

M-A: Omega-3 fatty acids supplementation increases the risk of atrial fibrillation in patients with lipid disorders.

10 May, 2021 | 01:00h | UTC

Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials – European Heart Journal – Cardiovascular Pharmacotherapy

Commentaries: Fish oil supplements linked with heart rhythm disorder – European Society of Cardiology AND Could High-Dose Fish Oil Raise Odds for A-Fib in Heart Patients? – HealthDay

 

Commentary on Twitter

 

[#ACC21 – not published yet] 1 in 5 adults with high blood pressure also take a medicine that could be elevating their blood pressure.

10 May, 2021 | 00:58h | UTC

Have high blood pressure? You may want to check your meds – American College of Cardiology

Commentary: Are You Taking a Med That’s Raising Your Blood Pressure? – HealthDay

 

Drugs tested in low- and middle-income countries are often not available for use in these countries even after a few years.

10 May, 2021 | 00:54h | UTC

Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs – JAMA Network Open

 

Commentary on Twitter

 

Review: Colchicine and the heart.

10 May, 2021 | 00:56h | UTC

Colchicine and the heart – European Heart Journal

Related meta-analysis: Colchicine administration for percutaneous coronary intervention

Related randomized trials: Colchicine in patients with chronic coronary disease (study and commentaries) AND Low-Dose Colchicine Improves Outcomes after Myocardial Infarction (study and commentaries) AND Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) (study and commentary)

 

Commentary on Twitter

 

RCT: Efficacy and safety of voclosporin for lupus nephritis – voclosporin + MMF + low dose corticosteroids achieved complete renal response at week 52 more often than MMF + low dose corticosteroids alone (41% vs. 23%).

10 May, 2021 | 00:48h | UTC

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial – The Lancet (link to abstract – $ for full-text)

 

RCT: Community pharmacies provision of a progestogen-only pill + invitation to a sexual and reproductive health clinic as a bridging contraception intervention for women receiving emergency contraception is associated with increased subsequent use of long-term effective contraception.

10 May, 2021 | 00:45h | UTC

Provision of the progestogen-only pill by community pharmacies as bridging contraception for women receiving emergency contraception: the Bridge-it RCT – Health Technology Assessment

 

WHO calls for pharma transparency in clinical trial data reporting.

10 May, 2021 | 00:39h | UTC

WHO Calls For Pharma Transparency In Clinical Trial Data Reporting – Health Policy Watch

WHO Statement: Joint Statement on transparency and data integrity International Coalition of Medicines Regulatory Authorities (ICMRA) and WHO

 

Commentary on Twitter

 

Cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S. 11 excess venous thromboembolic events per 100 000 vaccinations; 2.5 excess cerebral venous thrombosis per 100 000 vaccinations.

7 May, 2021 | 08:33h | UTC

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study – The BMJ

Editorial: Thromboembolism and the Oxford-AstraZeneca vaccine – The BMJ

Commentaries: Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination – The BMJ Opinion AND Putting risks into context: covid-19 vaccines and blood clots – The BMJ Opinion AND Expert reaction to study from Denmark and Norway looking at rare blood clots after the Oxford-AstraZeneca vaccine – Science Media Centre

 

Commentary on Twitter

 

Opinion | Covid-19: Sputnik vaccine rockets, thanks to Lancet boost

7 May, 2021 | 08:31h | UTC

Covid-19: Sputnik vaccine rockets, thanks to Lancet boost – The BMJ

 

Commentary on Twitter

 

RCT: Therapeutic drug monitoring during infliximab induction does not improve disease remission in patients with chronic immune-mediated inflammatory diseases

7 May, 2021 | 08:27h | UTC

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases – JAMA (free for a limited period)

Commentary: Mixed Results with Refined Treatment Strategies for Rheumatic Diseases – Physician’s Weekly

 

Commentary on Twitter

 

RCT: Among patients with rheumatoid arthritis in remission, tapering conventional DMARDs using half-dose resulted in disease flares in 25% of patients compared with 6% of patients in the stable-dose group.

7 May, 2021 | 08:26h | UTC

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases – JAMA (free for a limited period)

Commentary: Mixed Results with Refined Treatment Strategies for Rheumatic Diseases – Physician’s Weekly

 

In shock move, US backs waiving patents on COVID vaccines. “The development from the Biden administration draws cheers from public health researchers and ire from drugmakers.”

6 May, 2021 | 09:10h | UTC

In shock move, US backs waiving patents on COVID vaccines – Nature

See also: U.S. will back proposal to waive intellectual property rights and boost Covid-19 vaccine production – STAT AND Statement from the Executive Director of UNAIDS, Winnie Byanyima on the decision by the United States of America to support the TRIPS waiver for COVID-19 vaccines – UNAIDS AND WHO Director-General commends United States decision to support temporary waiver on intellectual property rights for COVID-19 vaccines – World Health Organization

 

Commentary on Twitter

 

Cohort study shows inadequate antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients.

6 May, 2021 | 09:01h | UTC

Antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients – Prospective cohort study – Clinical Microbiology and Infection

 

Commentary on Twitter

https://twitter.com/hildabast/status/1390097665451462656

 

Observational study in Israel: Pfizer-BioNTech is 95.3% effective against SARS-CoV-2 infection.

6 May, 2021 | 09:04h | UTC

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data – The Lancet

Commentaries: Expert reaction to Israel nation-wide study looking at Pfizer vaccine effectiveness – Science Media Centre AND Covid-19: Two doses of Pfizer vaccine are “highly effective” against infection, hospital admission, and death, study finds – The BMJ

 

Short review: How to diagnose and manage QT prolongation in cancer patients

7 May, 2021 | 08:18h | UTC

How to Diagnose and Manage QT Prolongation in Cancer Patients – JACC: CardioOncology

 

Commentary on Twitter (thread – click for more)

 

Observational study in Qatar: Pfizer–BioNTech Covid vaccine is 89.5% effective against B.1.1.7 variant and 75.0% effective against B.1.351 variant. Vaccine effectiveness against severe, critical, or fatal disease with any SARS-CoV-2 variant was very high, at 97.4%.

6 May, 2021 | 09:06h | UTC

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants – New England Journal of Medicine

Commentary: Pfizer-BioNTech vaccine offers strong protection against key variants of concern, real-world data from Qatar shows – The Washington Post

 

Commentary on Twitter

https://twitter.com/DrEricDing/status/1390107362485211136

 

RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.

6 May, 2021 | 09:08h | UTC

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant – New England Journal of Medicine

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.